Daptomycin resistance in enterococci is associated with distinct alterations of cell membrane phospholipid content

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Mishra, Nagendra N ^a   Bayer, Arnold S ^a,b   Tran, Truc T ^c,d   Shamoo, Yousif ^e   Mileykovskaya, Eugenia ^c   Dowhan, William ^c   Guan, Ziqiang ^f   Arias, Cesar A ^c,g  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF HOUSTON   (United States)

^e RICE UNIVERSITY   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSIDAD EL BOSQUE   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN; DAPTOMYCIN; GLYCEROLPHOSPHO DIGLYCODIACYLGLYCEROL; LYSOPHOSPHATIDYLGLYCEROL; PHOSPHATIDIC ACID; PHOSPHATIDYLGLYCEROL; PHOSPHOLIPID; UNCLASSIFIED DRUG; UNSATURATED FATTY ACID;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL MEMBRANE; CELL MEMBRANE DEPOLARIZATION; CELL MEMBRANE PERMEABILITY; CELL STRUCTURE; CELL SURFACE; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; LIPID COMPOSITION; MEMBRANE FLUIDITY; NONHUMAN; RIGIDITY; SIGNAL TRANSDUCTION; THICKNESS; TRANSMISSION ELECTRON MICROSCOPY;

ANTI-BACTERIAL AGENTS; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CELL WALL; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FATTY ACIDS; HUMANS; MEMBRANE FLUIDITY; MEMBRANE POTENTIALS; PHOSPHOLIPIDS; SPECIES SPECIFICITY; TREATMENT FAILURE;

EID: 84865404721     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043958     Document Type: Article

References (49)

1. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, et al. (2008) NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 29: 996-1011.
2. Rice LB, (2008) Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 197: 1079-1081.
3. Panesso D, Reyes J, Rincon S, Diaz L, Galloway-Pena J, et al. (2010) Molecular epidemiology of vancomycin-resistant Enterococcus faecium: a prospective, multicenter study in South American hospitals. J Clin Microbiol 48: 1562-1569.
4. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, et al. (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355: 653-665.
5. Twilla JD, Finch CK, Usery JB, Gelfand MS, Hudson JQ, et al. (2011) Vancomycin-resistant Enterococcus bacteremia: An evaluation of treatment with linezolid or daptomycin. J Hosp Med 7: 243-238.
6. Mave V, Garcia-Diaz J, Islam T, Hasbun R, (2009) Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? J Antimicrob Chemother 64: 175-180.
7. Munoz-Price LS, Lolans K, Quinn JP, (2005) Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis 41: 565-566.
8. Lewis JS 2nd, Owens A, Cadena J, Sabol K, Patterson JE, et al (2005) Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 49: 1664-1665.
9. Green MR, Anasetti C, Sandin RL, Rolfe NE, Greene JN, (2006) Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans. J Oncol Pharm Pract 12: 179-181.
10. Silverman JA, Perlmutter NG, Shapiro HM, (2003) Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 47: 2538-2544.
11. Pogliano J, Pogliano N, Silverman J (2012) Daptomycin mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. J Bacteriol: In press.
12. Mehta S, Cuirolo AX, Plata KB, Riosa S, Silverman JA, et al. (2012) VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 56: 92-102.
13. Arias CA, Panesso D, McGrath DM, Qin X, Mojica MF, et al. (2011) Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 365: 892-900.
14. Peleg AY, Miyakis S, Ward DV, Earl AM, Rubio A, et al. (2012) Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One 7: e28316.
15. Yang SJ, Xiong YQ, Dunman PM, Schrenzel J, Francois P, et al. (2009) Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 53: 2636-2637.
16. Palmer KL, Daniel A, Hardy C, Silverman J, Gilmore MS, (2011) Genetic basis for daptomycin resistance in enterococci. Antimicrobial agents and chemotherapy 55: 3345-3356.
17. Hachmann AB, Sevim E, Gaballa A, Popham DL, Antelmann H, et al. (2011) Reduction in membrane phosphatidylglycerol content leads to daptomycin resistance in Bacillus subtilis. Antimicrob Agents Chemother 55: 4326-4337.
18. Cui L, Isii T, Fukuda M, Ochiai T, Neoh HM, et al. (2010) An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob Agents Chemother 54: 5222-5233.
19. Jones T, Yeaman MR, Sakoulas G, Yang SJ, Proctor RA, et al. (2008) Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 52: 269-278.
20. Sader HS, Jones RN, (2009) Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). Diagn Microbiol Infect Dis 65: 158-162.
21. dos Santos Mota JM, den Kamp JA, Verheij HM, van Deenen LL, (1970) Phospholipids of Streptococcus faecalis. J Bacteriol 104: 611-619.
22. Bao Y, Sakinc T, Laverde D, Wobser D, Benachour A, et al. (2012) Role of mprF1 and mprF2 in the pathogenicity of Enterococcus faecalis. PLoS ONE 7: e38458.
23. Ernst CM, Staubitz P, Mishra NN, Yang SJ, Hornig G, et al. (2009) The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS pathogens 5: e1000660.
24. Rubio A, Moore J, Varoqlu M, Conrad M, Chu M, et al. (2012) LC-MS/MS characterization of phospholipid content in daptomycin-susceptible and-resistant isolates of Staphylococcus aureus with mutations in mprF. Mol Membr Biol 29: 1-8.
25. Sakayori Y, Muramatsu M, Hanada S, Kamagata Y, Kawamoto S, et al. (2003) Characterization of Enterococcus faecium mutants resistant to mundticin KS, a class IIa bacteriocin. Microbiology 149: 2901-2908.
26. Zhang YM, Rock CO, (2008) Membrane lipid homeostasis in bacteria. Nat Rev Microbiol 6: 222-233.
27. Zhang W, Campbell HA, King SC, Dowhan W, (2005) Phospholipids as determinants of membrane protein topology. Phosphatidylethanolamine is required for the proper topological organization of the gamma-aminobutyric acid permease (GabP) of Escherichia coli. J Biol Chem 280: 26032-26038.
28. Mileykovskaya E, Dowhan W, (2009) Cardiolipin membrane domains in prokaryotes and eukaryotes. Biochim Biophys Acta 1788: 2084-2091.
29. Goldberg DE, Rumley MK, Kennedy EP, (1981) Biosynthesis of membrane-derived oligosaccharides: a periplasmic phosphoglyceroltransferase. Proc Natl Acad Sci U S A 78: 5513-5517.
30. Dowhan W, (1997) Molecular basis for membrane phospholipid diversity: why are there so many lipids? Annu Rev Biochem 66: 199-232.
31. Fischer W, Ishizuka I, Landgraf HR, Herrmann J, (1973) Glycerophosphoryl diglucosyl diglyceride, a new phosphoglycolipid from Streptococci. Biochim Biophys Acta 296: 527-545.
32. Ambron RT, Pieringer RA, (1971) The metabolism of glyceride glycolipids. V. Identification of the membrane lipid formed from diglucosyl diglyceride in Streptococcus faecalis ATCC 9790 as an acylated derivative of glyceryl phosphoryl diglucosyl glycerol. J Biol Chem 246: 4216-4225.
33. Fischer W, Landgraf HR, Herrmann J, (1973) Phosphatidyldiglucosyl diglyceride from Streptococci and its relationship to other polar lipids. Biochim Biophys Acta 306: 353-367.
34. Fischer W, Landgraf HR, (1975) Glycerophosphoryl phosphatidyl kojibiosyl diacylglycerol, a novel phosphoglucolipid from Streptococcus faecalis. Biochim Biophys Acta 380: 227-244.
35. Carson DD, Pieringer RA, Daneo-Moore L, (1981) Effect of cerulenin on cellular autolytic activity and lipid metabolism during inhibition of protein synthesis in Streptococcus faecalis. J Bacteriol 146: 590-604.
36. Ganfield MC, Pieringer RA, (1980) The biosynthesis of nascent membrane lipoteichoic acid of Streptococcus faecium (S. faecalis ATCC 9790) from phosphatidylkojibiosyl diacylglycerol and phosphatidylglycerol. J Biol Chem 255: 5164-5169.
37. Bertsche U, Weidenmaier C, Kuehner D, Yang SJ, Baur S, et al. (2011) Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation. Antimicrob Agents Chemother 55: 3922-3928.
38. Yang SJ, Kreiswirth BN, Sakoulas G, Yeaman MR, Xiong YQ, et al. (2009) Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis 200: 1916-1920.
39. Mishra NN, Yang SJ, Sawa A, Rubio A, Nast CC, et al. (2009) Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 53: 2312-2318.
40. Xiong YQ, Mukhopadhyay K, Yeaman MR, Adler-Moore J, Bayer AS, (2005) Functional interrelationships between cell membrane and cell wall in antimicrobial peptide-mediated killing of Staphylococcus aureus. Antimicrob Agents Chemother 49: 3114-3121.
41. Glickman MS, Cox JS, Jacobs WR Jr, (2000) A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol Cell 5: 717-727.
42. Dutka-Malen S, Evers S, Courvalin P, (1995) Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J Clin Microbiol 33: 1434.
43. Dixit BL, Gupta CM, (1998) Role of the actin cytoskeleton in regulating the outer phosphatidylethanolamine levels in yeast plasma membrane. Eur J Biochem 254: 202-206.
44. Mukhopadhyay K, Whitmire W, Xiong YQ, Molden J, Jones T, et al. (2007) In vitro susceptibility of Staphylococcus aureus to thrombin-induced platelet microbicidal protein-1 (tPMP-1) is influenced by cell membrane phospholipid composition and asymmetry. Microbiology 153: 1187-1197.
45. Tsai M, Ohniwa R, Kato Y, Takeshita S, Ohta T, et al. (2011) Staphylococcus aureus requires cardiolipin for survival under conditions of high salinity. BMC microbiology 11: 13.
46. Bayer AS, Prasad R, Chandra J, Koul A, Smriti M, et al. (2000) In vitro resistance of Staphylococcus aureus to thrombin-induced platelet microbicidal protein is associated with alterations in cytoplasmic membrane fluidity. Infect Immun 68: 3548-3553.
47. Peschel A, Otto M, Jack RW, Kalbacher H, Jung G, et al. (1999) Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem 274: 8405-8410.
48. Leuko S, Legat A, Fendrihan S, Stan-Lotter H, (2004) Evaluation of the LIVE/DEAD BacLight kit for detection of extremophilic archaea and visualization of microorganisms in environmental hypersaline samples. Appl Environ Microbiol 70: 6884-6886.
49. Higgins DL, Chang R, Debabov DV, Leung J, Wu T, et al. (2005) Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 49: 1127-1134.